Bronchopulmonary dysplasia risk following antenatal corticosteroids in low-birth-weight non-late preterm infants: a meta-analysis
6 affiliations
- 1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University
- 2Bia-Echo Asia Centre for Reproductive Longevity and Equality (ACRLE), Yong Loo Lin School of Medicine, National University of Singapore
- 3Department of Neonatology, Women and Children’s Hospital of Chongqing Medical University, Chongqing Health Center for Women and Children
- 4Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children’s Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics
- 5Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore
- 6Department of Neonatology, Khoo Teck Puat National University Children’s Medical Institute, National University Hospital, National University Health System
Abstract
Background Early antenatal corticosteroids (ACS) are widely recommended for women at risk of preterm delivery to prevent neonatal death and neurocognitive impairment, yet inconsistent evidence has reported its impact on bronchopulmonary dysplasia (BPD). We aimed to systematically investigate risks of BPD as well as other major neonatal adverse outcomes among preterm infants. Methods This meta-analysis searched PubMed, EMBASE, Cochrane CENTRAL, Web of Science, CINAHL Plus, PsycInfo (OvidSP), and ClinicalTrials.gov from 1st January 1990 to 31st March 2026. Four reviewers independently screened records, extracted data, and assessed risk of bias using Cochrane tools for randomized clinical trials (RCTs) and the Newcastle-Ottawa Scale for cohort studies. Exposures was the administration of early ACS prior to preterm delivery. The primary outcome was a composite of neonatal death or BPD, and BPD alone among survivors. Secondary outcomes included composites of neonatal death or retinopathy of prematurity (ROP) and neonatal death or neurodevelopmental impairment (NDI), alongside incidences of chorioamnionitis, respiratory distress syndrome (RDS), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), and periventricular leukomalacia (PVL). Pooled risk ratios (RRs) with 95% CIs were calculated using random-effects models. Results Thirty-four studies (4 RCTs, 30 cohorts) with 55,284 infants were included. ACS reduced the risk of the death/BPD composite (RR, 0.90; 95% CI, 0.83–0.98) but not BPD alone (RR, 1.04; 95% CI, 0.93–1.15). ACS reduced risks for the death/ROP composite (RR, 0.79; 95% CI, 0.72–0.87), the death/NDI composite (RR, 0.72; 95% CI, 0.67–0.78), NDI alone (RR, 0.78; 95% CI, 0.73–0.82), RDS, IVH, and PVL. ACS did not affect ROP alone or NEC, but increased chorioamnionitis risk (RR, 1.32; 95% CI, 1.10–1.58). Stratification by gestational age (≤28 weeks versus >28 weeks of gestation) or birth weight (<1500 g versus 1500–2500 g) did not alter findings. Conclusions In non-late preterm, low-birth-weight infants, early ACS demonstrated overall neonatal benefits but did not reduce the risk of BPD or ROP when assessed independently among survivors. The associated increased risk of chorioamnionitis warrants careful clinical consideration. Future research requires extended follow-up to evaluate multi-systemic developmental outcomes. Trial registration PROSPERO (CRD420251154695)
Related
- Hospital-Level Variation in Antenatal Corticosteroids for Late Preterm Births
- How should hydrocortisone be used for bronchopulmonary dysplasia in preterm infants?
- Safety risk identification and family empowerment needs in home oxygen therapy for preterm infants with bronchopulmonary dysplasia: a qualitative study
- Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants-A Systematic Review.
- Effects of Neurally Adjusted Ventilatory Assist on Lung Ultrasound Aeration and Diaphragmatic Function in Extremely Preterm Infants With Evolving or Established Bronchopulmonary Dysplasia.
BibTeX
@article{li2026bronchopulmonary,
title = {{Bronchopulmonary dysplasia risk following antenatal corticosteroids in low-birth-weight non-late preterm infants: a meta-analysis}},
author = {Jie Li and Qian Yang and Qin Tan and Fang Li and Yuan Shi and Sebastian E. Illanes and Ayca Altay Benetti and Mahesh Choolani and Jiun Lee and Hongbo Qi and Wei Zhou and Ling-Jun Li and Long Chen},
journal = {BMC Medicine},
year = {2026},
month = aug,
doi = {10.1186/s12916-026-05125-y},
url = {https://doi.org/10.1186/s12916-026-05125-y},
note = {CC BY},
}
RIS
TY - JOUR
TI - Bronchopulmonary dysplasia risk following antenatal corticosteroids in low-birth-weight non-late preterm infants: a meta-analysis
AU - Jie Li
AU - Qian Yang
AU - Qin Tan
AU - Fang Li
AU - Yuan Shi
AU - Sebastian E. Illanes
AU - Ayca Altay Benetti
AU - Mahesh Choolani
AU - Jiun Lee
AU - Hongbo Qi
AU - Wei Zhou
AU - Ling-Jun Li
AU - Long Chen
PY - 2026
DA - 2026/08/01
JO - BMC Medicine
DO - 10.1186/s12916-026-05125-y
UR - https://doi.org/10.1186/s12916-026-05125-y
AB - Background Early antenatal corticosteroids (ACS) are widely recommended for women at risk of preterm delivery to prevent neonatal death and neurocognitive impairment, yet inconsistent evidence has reported its impact on bronchopulmonary dysplasia (BPD). We aimed to systematically investigate risks of BPD as well as other major neonatal adverse outcomes among preterm infants. Methods This meta-analysis searched PubMed, EMBASE, Cochrane CENTRAL, Web of Science, CINAHL Plus, PsycInfo (OvidSP), and ClinicalTrials.gov from 1st January 1990 to 31st March 2026. Four reviewers independently screened records, extracted data, and assessed risk of bias using Cochrane tools for randomized clinical trials (RCTs) and the Newcastle-Ottawa Scale for cohort studies. Exposures was the administration of early ACS prior to preterm delivery. The primary outcome was a composite of neonatal death or BPD, and BPD alone among survivors. Secondary outcomes included composites of neonatal death or retinopathy of prematurity (ROP) and neonatal death or neurodevelopmental impairment (NDI), alongside incidences of chorioamnionitis, respiratory distress syndrome (RDS), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), and periventricular leukomalacia (PVL). Pooled risk ratios (RRs) with 95% CIs were calculated using random-effects models. Results Thirty-four studies (4 RCTs, 30 cohorts) with 55,284 infants were included. ACS reduced the risk of the death/BPD composite (RR, 0.90; 95% CI, 0.83–0.98) but not BPD alone (RR, 1.04; 95% CI, 0.93–1.15). ACS reduced risks for the death/ROP composite (RR, 0.79; 95% CI, 0.72–0.87), the death/NDI composite (RR, 0.72; 95% CI, 0.67–0.78), NDI alone (RR, 0.78; 95% CI, 0.73–0.82), RDS, IVH, and PVL. ACS did not affect ROP alone or NEC, but increased chorioamnionitis risk (RR, 1.32; 95% CI, 1.10–1.58). Stratification by gestational age (≤28 weeks versus >28 weeks of gestation) or birth weight (<1500 g versus 1500–2500 g) did not alter findings. Conclusions In non-late preterm, low-birth-weight infants, early ACS demonstrated overall neonatal benefits but did not reduce the risk of BPD or ROP when assessed independently among survivors. The associated increased risk of chorioamnionitis warrants careful clinical consideration. Future research requires extended follow-up to evaluate multi-systemic developmental outcomes. Trial registration PROSPERO (CRD420251154695)
SN - 1741-7015
ER -